Impact of CYP2D6 genotype on fluoxetine exposure and treatment switch in adults and children/adolescents.

Nordby KL, Faraj P, Molden E, Hole K

Open source

DOI
10.1007/s00228-025-03893-9
Published
2025 Nov
Container
European journal of clinical pharmacology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s00228-025-03893-9,
  title = {Impact of CYP2D6 genotype on fluoxetine exposure and treatment switch in adults and children/adolescents.},
  author = {Nordby KL and Faraj P and Molden E and Hole K},
  year = {2025},
  journal = {European journal of clinical pharmacology},
  doi = {10.1007/s00228-025-03893-9},
  url = {https://doi.org/10.1007/s00228-025-03893-9}
}

RIS

TY  - JOUR
TI  - Impact of CYP2D6 genotype on fluoxetine exposure and treatment switch in adults and children/adolescents.
AU  - Nordby KL
AU  - Faraj P
AU  - Molden E
AU  - Hole K
PY  - 2025
JO  - European journal of clinical pharmacology
DO  - 10.1007/s00228-025-03893-9
UR  - https://doi.org/10.1007/s00228-025-03893-9
ER  - 

APA

KL, N., P, F., E, M., & K, H. (2025). Impact of CYP2D6 genotype on fluoxetine exposure and treatment switch in adults and children/adolescents.. European journal of clinical pharmacology. https://doi.org/10.1007/s00228-025-03893-9

Source records